CO6680717A2 - Derivados de quinolina y quinoxalina como inhibidores de cinasa - Google Patents

Derivados de quinolina y quinoxalina como inhibidores de cinasa

Info

Publication number
CO6680717A2
CO6680717A2 CO13056775A CO13056775A CO6680717A2 CO 6680717 A2 CO6680717 A2 CO 6680717A2 CO 13056775 A CO13056775 A CO 13056775A CO 13056775 A CO13056775 A CO 13056775A CO 6680717 A2 CO6680717 A2 CO 6680717A2
Authority
CO
Colombia
Prior art keywords
quinoline
quinoxaline derivatives
kinase inhibitors
present
quinoxaline
Prior art date
Application number
CO13056775A
Other languages
English (en)
Inventor
Andrew Harry Parton
Mezher Hussein Ali
Daniel Christopher Brookings
Julien Alistair Brown
Daniel James Ford
Richard Jeremy Franklin
Barry John Langham
Judi Charlotte Neuss
Joanna Rachel Quincey
Original Assignee
Ucb Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45810169&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6680717(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB1014963.1A external-priority patent/GB201014963D0/en
Priority claimed from GBGB1101128.5A external-priority patent/GB201101128D0/en
Application filed by Ucb Pharma Sa filed Critical Ucb Pharma Sa
Publication of CO6680717A2 publication Critical patent/CO6680717A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Abstract

La presente invención se refiere a una clase de derivados de quinolina y quinoxalina, y a su uso en terapia. En una de las modalidades, la presente invención provee un compuesto de fórmula (I) o un N-óxido del mismo, o una sal farmacéuticamente aceptable o solvato del mismo:
CO13056775A 2010-09-08 2013-03-21 Derivados de quinolina y quinoxalina como inhibidores de cinasa CO6680717A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1014963.1A GB201014963D0 (en) 2010-09-08 2010-09-08 Therapeutic agents
GBGB1101128.5A GB201101128D0 (en) 2011-01-21 2011-01-21 Therapeutic agents

Publications (1)

Publication Number Publication Date
CO6680717A2 true CO6680717A2 (es) 2013-05-31

Family

ID=45810169

Family Applications (1)

Application Number Title Priority Date Filing Date
CO13056775A CO6680717A2 (es) 2010-09-08 2013-03-21 Derivados de quinolina y quinoxalina como inhibidores de cinasa

Country Status (33)

Country Link
US (1) US9029392B2 (es)
EP (1) EP2614061B1 (es)
JP (1) JP5820882B2 (es)
KR (1) KR101880280B1 (es)
CN (1) CN103153996B (es)
AR (1) AR082799A1 (es)
AU (1) AU2011300521B2 (es)
BR (1) BR112013004750B1 (es)
CA (1) CA2808959C (es)
CL (1) CL2013000603A1 (es)
CO (1) CO6680717A2 (es)
CY (1) CY1116734T1 (es)
DK (1) DK2614061T3 (es)
EA (1) EA024162B1 (es)
ES (1) ES2544289T3 (es)
HK (1) HK1181754A1 (es)
HR (1) HRP20150868T1 (es)
HU (1) HUE025223T2 (es)
IL (1) IL224841A (es)
MA (1) MA34600B1 (es)
ME (1) ME02203B (es)
MX (1) MX2013002529A (es)
MY (1) MY162396A (es)
NZ (1) NZ607966A (es)
PL (1) PL2614061T3 (es)
PT (1) PT2614061E (es)
RS (1) RS54202B1 (es)
SG (1) SG187924A1 (es)
SI (1) SI2614061T1 (es)
SM (1) SMT201500195B (es)
TW (1) TWI510489B (es)
WO (1) WO2012032334A1 (es)
ZA (1) ZA201301751B (es)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3613743B1 (en) 2008-01-04 2022-03-16 Intellikine, LLC Processes for the preparation of 1h-pyrazolo[3,4-d]pyrimidin-4-amine derivatives
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
EP2346508B1 (en) 2008-09-26 2016-08-24 Intellikine, LLC Heterocyclic kinase inhibitors
CA2760791C (en) 2009-05-07 2017-06-20 Intellikine, Inc. Heterocyclic compounds and uses thereof
US8604032B2 (en) 2010-05-21 2013-12-10 Infinity Pharmaceuticals, Inc. Chemical compounds, compositions and methods for kinase modulation
AR082799A1 (es) * 2010-09-08 2013-01-09 Ucb Pharma Sa Derivados de quinolina y quinoxalina como inhibidores de quinasa
WO2012064973A2 (en) 2010-11-10 2012-05-18 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US8754114B2 (en) 2010-12-22 2014-06-17 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
TWI674262B (zh) 2011-01-10 2019-10-11 美商英菲尼提製藥股份有限公司 製備異喹啉酮之方法及異喹啉酮之固體形式
KR20140063605A (ko) 2011-07-19 2014-05-27 인피니티 파마슈티칼스, 인코포레이티드 헤테로사이클릭 화합물 및 그의 용도
AU2012284088B2 (en) 2011-07-19 2015-10-08 Infinity Pharmaceuticals Inc. Heterocyclic compounds and uses thereof
RU2014111823A (ru) 2011-08-29 2015-10-10 Инфинити Фармасьютикалз, Инк. Гетероциклические соединения и их применения
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
AU2013287176C1 (en) 2012-06-13 2023-01-19 Incyte Holdings Corporation Substituted tricyclic compounds as FGFR inhibitors
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
US9388185B2 (en) 2012-08-10 2016-07-12 Incyte Holdings Corporation Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
US9481667B2 (en) 2013-03-15 2016-11-01 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
UA120087C2 (uk) 2013-04-19 2019-10-10 Інсайт Холдинґс Корпорейшн Біциклічні гетероцикли як інгібітори fgfr
WO2015051241A1 (en) 2013-10-04 2015-04-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
HUE057734T2 (hu) 2013-10-04 2022-06-28 Infinity Pharmaceuticals Inc Heterociklusos vegyületek és alkalmazásuk
CN104744435B (zh) * 2013-12-25 2017-03-01 上海医药工业研究院 喹啉类化合物、其盐、其中间体、制备方法及应用
CN106456628A (zh) 2014-03-19 2017-02-22 无限药品股份有限公司 用于治疗PI3K‑γ介导的障碍的杂环化合物
WO2015160975A2 (en) 2014-04-16 2015-10-22 Infinity Pharmaceuticals, Inc. Combination therapies
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
WO2016134294A1 (en) 2015-02-20 2016-08-25 Incyte Corporation Bicyclic heterocycles as fgfr4 inhibitors
ES2751669T3 (es) 2015-02-20 2020-04-01 Incyte Corp Heterociclos bicíclicos como inhibidores FGFR
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
GB201506786D0 (en) * 2015-04-21 2015-06-03 Ucb Biopharma Sprl Therapeutic use
EP3350183A1 (en) 2015-09-14 2018-07-25 Infinity Pharmaceuticals, Inc. Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same
WO2017161116A1 (en) 2016-03-17 2017-09-21 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
GB201604970D0 (en) 2016-03-23 2016-05-04 Syngenta Participations Ag Improvements in or relating to organic compounds
GB201608797D0 (en) * 2016-05-19 2016-07-06 Ucb Biopharma Sprl Therapeutic use
WO2017214269A1 (en) 2016-06-08 2017-12-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
SG10201912456RA (en) 2016-06-24 2020-02-27 Infinity Pharmaceuticals Inc Combination therapies
CN108239076B (zh) * 2016-12-26 2021-07-06 中国医学科学院药物研究所 喹唑啉类化合物及其制备方法、用途和药物组合物
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
GB201708856D0 (en) * 2017-06-02 2017-07-19 Ucb Biopharma Sprl Seletalisib crystalline forms
CA3099116A1 (en) 2018-05-04 2019-11-07 Incyte Corporation Salts of an fgfr inhibitor
JP2021523121A (ja) 2018-05-04 2021-09-02 インサイト・コーポレイションＩｎｃｙｔｅ Ｃｏｒｐｏｒａｔｉｏｎ Ｆｇｆｒ阻害剤の固体形態及びその調製プロセス
US11628162B2 (en) 2019-03-08 2023-04-18 Incyte Corporation Methods of treating cancer with an FGFR inhibitor
WO2021007269A1 (en) 2019-07-09 2021-01-14 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
CR20220169A (es) 2019-10-14 2022-10-27 Incyte Corp Heterociclos bicíclicos como inhibidores de fgfr
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
CA3163875A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
BR112022010664A2 (pt) 2019-12-04 2022-08-16 Incyte Corp Derivados de um inibidor de fgfr
AR126102A1 (es) 2021-06-09 2023-09-13 Incyte Corp Heterociclos tricíclicos como inhibidores de fgfr

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2139882T3 (pl) 2007-03-23 2014-05-30 Amgen Inc 3-podstawione pochodne chinoliny lub chinoksaliny i ich zastosowanie jako inhibitorów 3-kinazy fosfatydyloinozytolu (pi3k)
JP2010522177A (ja) * 2007-03-23 2010-07-01 アムジエン・インコーポレーテツド 複素環化合物およびその使用
KR101504773B1 (ko) * 2007-03-23 2015-03-20 암젠 인크 헤테로시클릭 화합물 및 그의 용도
US8399483B2 (en) 2007-12-21 2013-03-19 Ucb Pharma S.A. Quinoxaline and quinoline derivatives as kinase inhibitors
GB0819593D0 (en) * 2008-10-24 2008-12-03 Ucb Pharma Sa Therapeutic agents
WO2011058108A1 (en) * 2009-11-12 2011-05-19 Ucb Pharma S.A. Quinoline and quinoxaline derivatives as kinase inhibitors
AR082799A1 (es) * 2010-09-08 2013-01-09 Ucb Pharma Sa Derivados de quinolina y quinoxalina como inhibidores de quinasa

Also Published As

Publication number Publication date
SG187924A1 (en) 2013-03-28
EA024162B1 (ru) 2016-08-31
WO2012032334A1 (en) 2012-03-15
JP5820882B2 (ja) 2015-11-24
CA2808959C (en) 2018-07-17
CY1116734T1 (el) 2017-03-15
PL2614061T3 (pl) 2015-11-30
US9029392B2 (en) 2015-05-12
AU2011300521A1 (en) 2013-04-04
BR112013004750A2 (pt) 2016-08-02
DK2614061T3 (en) 2015-08-10
ZA201301751B (en) 2014-05-28
EA201300317A1 (ru) 2013-11-29
CN103153996A (zh) 2013-06-12
HK1181754A1 (en) 2013-11-15
AR082799A1 (es) 2013-01-09
EP2614061A1 (en) 2013-07-17
MX2013002529A (es) 2013-10-28
JP2013537183A (ja) 2013-09-30
SI2614061T1 (sl) 2015-08-31
US20130296338A1 (en) 2013-11-07
CA2808959A1 (en) 2012-03-15
PT2614061E (pt) 2015-10-01
AU2011300521B2 (en) 2017-05-25
IL224841A (en) 2017-03-30
NZ607966A (en) 2014-07-25
BR112013004750B1 (pt) 2021-06-15
TWI510489B (zh) 2015-12-01
CN103153996B (zh) 2016-01-27
KR20130139909A (ko) 2013-12-23
ES2544289T3 (es) 2015-08-28
ME02203B (me) 2016-02-20
KR101880280B1 (ko) 2018-07-20
MY162396A (en) 2017-06-15
RS54202B1 (en) 2015-12-31
MA34600B1 (fr) 2013-10-02
CL2013000603A1 (es) 2013-06-21
EP2614061B1 (en) 2015-05-20
HUE025223T2 (en) 2016-02-29
SMT201500195B (it) 2015-09-07
HRP20150868T1 (hr) 2015-09-25
TW201217371A (en) 2012-05-01

Similar Documents

Publication Publication Date Title
CO6680717A2 (es) Derivados de quinolina y quinoxalina como inhibidores de cinasa
UY39630A (es) Inhibidores de bromodominios
CY1122266T1 (el) Ενωσεις 3-αμινοκυκλοαλκυλιου ως ror-gamma-t αναστολεις και χρησεις αυτων
PH12016500024A1 (en) Bromodomain inhibitor
CR20150474A (es) Inhibidores de bromodominios tetracíclicos
CL2015000829A1 (es) Inhibidores de histona desmetilasas
TR201810944T4 (tr) Fgfr4 inhibitörleri olarak halka-füzyonlu bisiklik piridil türevleri.
MX2015012432A (es) Inhibidores piridinicos de la cinasa cdk9.
EA201391285A1 (ru) Производные тетрагидрохинолина, полезные в качестве ингибиторов бромодомена
EA202090291A3 (ru) Производные бипиразола в качестве ингибиторов jak
MX2015012005A (es) Inhibidores de bromodominio.
UA113651C2 (xx) Макроциклічні пурини для лікування вірусних інфекцій
BR112014033080A2 (pt) inibidores do vírus da hepatite c
BR112015000704A2 (pt) imidazotriazinacarbonitrilas úteis como inibidores de quinase
EA201590931A1 (ru) Гетероциклические замещенные производные 2-амино-хиназолина для лечения вирусных инфекций
EA201492188A1 (ru) Макроциклические ингибиторы вирусов flaviviridae
MX2015012431A (es) Pirrol amida como inhibidores.
EA201491671A1 (ru) Гетероциклильные соединения
EA201400333A1 (ru) Бензонитрильные производные в качестве ингибиторов киназ
EA201500628A1 (ru) Индолкарбоксамидные производные в качестве антагонистов p2xрецепторов
UY33888A (es) Derivados de (1,2,4) triazolo [4,3-a) quinoxalina como inhibidores de fosfodiesterasas
PH12015502118A1 (en) Pyridin-4-yl derivatives
EA201491376A1 (ru) Производные 1h-пирроло[2,3-b]пиридина и их применение в качестве ингибиторов киназы
UY34314A (es) Derivados de anilina, su preparación y su aplicación terapéutica.
EA201400822A1 (ru) Производные гетероциклических амидов в качестве антагонистов p2xрецептора

Legal Events

Date Code Title Description
FG Application granted